AbbVie (ABBV) Capital Expenditures (2012 - 2026)

AbbVie (ABBV) has 15 years of Capital Expenditures data on file, last reported at $265.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $265.0 million, up 12.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 22.44% YoY), and the FY2025 annual result was $1.2 billion, up 24.64% from the prior year.
• Capital Expenditures slipped to $265.0 million in Q1 2026 per ABBV's latest filing, from $329.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $381.0 million in Q3 2025 and troughed at $143.0 million in Q2 2022.
• A 5-year average of $230.9 million and a median of $219.0 million in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures dropped 26.67% in 2022, then jumped 53.01% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $213.0 million in 2022, then decreased by 3.76% to $205.0 million in 2023, then surged by 41.95% to $291.0 million in 2024, then advanced by 13.06% to $329.0 million in 2025, then retreated by 19.45% to $265.0 million in 2026.
• Business Quant data shows ABBV's Capital Expenditures at $265.0 million in Q1 2026, $329.0 million in Q4 2025, and $381.0 million in Q3 2025.